Genprex Reports Third Quarter 2026 Financial Results
Genprex, Inc. reported its financial results for the third quarter of 2026, noting continued zero revenue and an increase in operating losses.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Genprex, Inc. reported its financial results for the third quarter of 2026, noting continued zero revenue and an increase in operating losses.
Genprex announced that Dr. Pier-Anne Lachance will present on the company's dual-delivery approach for diabetes gene therapy at the upcoming Future of Cell and Gene Therapy Symposium.
Genprex announced new research findings from an analysis of blood samples from lung cancer patients treated with REQORSA, revealing shifts in gene expression related to cellular maintenance and repair.
Genprex announced new research identifying TROP2 expression as a potential predictive biomarker for response to its REQORSA gene therapy in non-small cell lung cancer.
Filed: 2026-11-04 AccNo: 0001437749-26-034764 Size: 172 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Genprex, Inc. announced new preclinical findings regarding the role of the TUSC2 gene in cellular function during brain aging.